REGN catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
- Completion LockedNo phase registeredNCT05568459A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care...Regeneron Pharmaceuticals · Hemophilia BActive, not recruitingREGNLead
- Enrollment
- Locked
- Primary completion
- Nov 20, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT05831176A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic...Regeneron Pharmaceuticals · Eosinophilic Gastritis (EoG)Active, not recruitingREGNLeadSNYCollaborator
- Enrollment
- Locked
- Primary completion
- Feb 23, 2026Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT04291105Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer PatientsVyriad, Inc. · MelanomaActive, not recruitingREGNCollaborator
- Enrollment
- Locked
- Primary completion
- Oct 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 4NCT06352073Dupilumab for Eosinophilic Esophagitis With Severe StricturesUniversity of North Carolina, Chapel Hill · Eosinophilic EsophagitisActive, not recruitingREGNCollaboratorSNYCollaborator
- Enrollment
- Locked
- Primary completion
- Apr 16, 2026Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT06421636A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron...Regeneron Pharmaceuticals · Non-Transfusion Dependent Beta-Thalassemia (NTDT)Active, not recruitingREGNLead
- Enrollment
- Locked
- Primary completion
- Dec 3, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT06452771A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe and Well Tolerated in Healthy AdultsRegeneron Pharmaceuticals · Healthy Volunteers With HyperlipidemiaActive, not recruitingREGNLead
- Enrollment
- Locked
- Primary completion
- Dec 4, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT07431086Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the USRegeneron Pharmaceuticals · Overweight or ObesityActive, not recruitingREGNLead
- Enrollment
- Locked
- Primary completion
- Nov 13, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 4NCT04380038Viral Infection in Asthma (VIA) StudyUniversity of Virginia · AsthmaRecruitingREGNCollaborator
- Enrollment
- Locked
- Primary completion
- Jun 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 4NCT05094570Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNPUniversity of Virginia · Nasal PolypsRecruitingREGNCollaborator
- Enrollment
- Locked
- Primary completion
- Jun 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT06491914A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular...Regeneron Pharmaceuticals · Neovascular Age-Related Macular DegenerationActive, not recruitingREGNLead
- Enrollment
- Locked
- Primary completion
- Aug 26, 2025Actual
- Interventions
- Locked
- Completion LockedPhase 1NCT07526116A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a Single Dose of REGN22044 in Healthy AdultsRegeneron Pharmaceuticals · Healthy VolunteerRecruitingREGNLead
- Enrollment
- Locked
- Primary completion
- Feb 8, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT06834360A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With...Sanofi · Chronic Rhinosinusitis With Nasal PolypsActive, not recruitingSNYLeadREGNCollaborator
- Enrollment
- Locked
- Primary completion
- Sep 24, 2026Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT07424144An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled...Sanofi · Chronic Rhinosinusitis With Nasal PolypsActive, not recruitingSNYLeadREGNCollaborator
- Enrollment
- Locked
- Primary completion
- Feb 17, 2027Sponsor estimate
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 13 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.